Nov 1, 2022
Axial Therapeutics CEO A. Stewart Campbell to Present at Microbiome Connect: USA 2022
Oct 11, 2022
Axial Therapeutics Expands Clinical Development Capabilities with Key Appointments
Sep 13, 2022
Axial Therapeutics CEO, A. Stewart Campbell, to Participate at the Longwood Healthcare Leaders Fall Webconference
July 13, 2022
Seed Health Launches Gut-Brain Development Program with Axial Therapeutics To Translate Caltech Research into Probiotic Innovations for Neuropsychiatric Health
May 2, 2022
Axial Therapeutics Announces Participation of its CEO, A. Stewart Campbell, in Longwood Healthcare Leaders Spring MIT Webconference
April 5, 2022
Axial Therapeutics’ Scientific Founder Sarkis Mazmanian, Ph.D., to Present Research Highlighting the Gut-Brain Connection in Autism Spectrum Disorder (ASD) at TACA’s Autism Action Conference
February 14, 2022
New Preclinical Research Published in Nature Highlights an Active Role by Microbiome-Derived Metabolites in Brain Function and Anxiety-like Behavior
February 14, 2022
Nature Medicine Publishes Full Results from Axial Therapeutics’ Phase 1b/2a Clinical Trial in Autism Spectrum Disorder (ASD)
November 30, 2021
Axial Therapeutics Doses First Subjects in Global Phase 2b Clinical Trial for Irritability Associated with Autism Spectrum Disorder (ASD)
October 27, 2021
Axial Therapeutics Receives FDA Clearance of IND Application and Initiates Phase 2b Trial for AB-2004, Lead Gut-Targeted, Molecular Therapeutic for the Treatment of Irritability in Autism Spectrum Disorder
October 13, 2021
Axial Therapeutics Raises $37.25 Million in Series C Financing to Advance its Pipeline of Gut-Targeted Small Molecule Drugs for Neurological Diseases and Disorders
